A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
Status:
Recruiting
Trial end date:
2027-07-31
Target enrollment:
Participant gender:
Summary
In this study, adults with newly-diagnosed Philadelphia Chromosome-positive acute
lymphoblastic leukemia (Ph+ ALL) will receive first-line therapy of ponatinib or imatinib.
The main aim of this study is to compare the number of participants on each treatment that
show no signs of disease.
Participants will take tablets of either ponatinib or imatinib at the same time each day
combined with reduced-intensity chemotherapy for up to 20 months. Then, they will continue
with single-agent therapy (ponatinib or imatinib) until they meet the discontinuation
criteria from the study.